General Announcement::iX Biopharma Expands Nutraceuticals Portfolio With Innovative Anti-Aging Sublingual NAD+ Product

(Co. Reg. No: 200405621W)

__________________________________________________________________________________________

NEWS RELEASE

iX Biopharma Expands Nutraceuticals Portfolio With

Innovative Anti-Aging Sublingual NAD+ Product

• 1st sublingual NAD+ wafer to deliver pure NAD+, instead of its precursors
• 3rd product in its popular NAD+ line-up and 3rd sublingual Entity Health
  product

Singapore, 26 October 2021 - Specialty pharmaceutical company iX Biopharma Ltd ("iX Biopharma" or, the "Group") has rolled out its game-changingSL-NAD+TM, a sublingual wafer containing pure nicotinamide adenine dinucleotide (NAD+), under its Entity Health nutraceutical brand.

For the first time ever, pure and intact NAD+, also known as the molecule of youth, can be delivered directly into the bloodstream through a convenient sublingual freeze-dried wafer, without the need for invasive intravenous drips or injections. The Company leveraged its patented WaferiX sublingual drug delivery technology and proprietary freeze-drying manufacturing process to stabilise and preserve the integrity of the otherwise volatile NAD+ molecule.

Dr Janakan Krishnarajah, Chief Operating Officer of iX Biopharma, said, "SL-NAD+ is differentiated from other nicotinamide supplements in the market in that it does not use precursors of NAD+ which need to be converted into NAD+ in the body. SL-NAD+ is the result of the successful incorporation of pure NAD+ into our WaferiX wafers, which is able to maintain the integrity of the active ingredient and disintegrate rapidly under the tongue for maximum absorption."

Found in every human cell, NAD+ is a coenzyme that plays a critical role in many of the human body's fundamental processes, such as converting nutrients into energy and maintaining cellular health and longevity. The loss of NAD+ levels with age is known to result in reduced energy, increased inflammation, and reduced cellular repair and organ function. These contribute to symptoms of aging such as fatigue, memory decline, joint and muscle pain, compromised immune function, increase susceptibility to infections and diseases. Replenishing the body's NAD+ levels thus helps to combat aging, support energy generation and activate sirtuins, which are proteins associated with delaying the aging process.

_________________________________________________________________________________________________

(Co. Reg. No: 200405621W)

__________________________________________________________________________________________

SL-NAD+ is the third sublingual product in the Entity Health portfolio, with the other two being LumeniX, a sublingual glutathione and WafeRest, a sublingual melatonin. SL-NAD+ is available on the www.entity-health.comweb store from 25 October 2021, and through its e- commerce channels in China, including Tmall Global and JD Worldwide, from November 2021.

________________

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma has developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The WaferiX delivery platform is particularly useful for drug repurposing which is a growing trend with a global market worth over US$30 billion1. Drug repurposing is where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia and Singapore. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

1 https://www.intechopen.com/books/drug-repurposing-hypothesis-molecular-aspects-and-therapeutic-applications/drug-repurposing-dr-an-emerging-approach-in-drug-discovery

_________________________________________________________________________________________________

(Co. Reg. No: 200405621W)

__________________________________________________________________________________________

Alvina Tan

Media & Investor Relations Consultant

T: +65 9787 7267

1. alvina.tan@arkadvisors.com.sg

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01- 01, Singapore 229957, telephone (65) 6590 6881.

_________________________________________________________________________________________________